Detalhes bibliográficos
| Ano de defesa: |
2016 |
| Autor(a) principal: |
Marques, Juliana Romeu
 |
| Orientador(a): |
Oliveira, Jarbas Rodrigues de
|
| Banca de defesa: |
Não Informado pela instituição |
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Pontifícia Universidade Católica do Rio Grande do Sul
|
| Programa de Pós-Graduação: |
Programa de Pós-Graduação em Biologia Celular e Molecular
|
| Departamento: |
Faculdade de Biociências
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
http://tede2.pucrs.br/tede2/handle/tede/6674
|
Resumo: |
The liraglutide is a glucagon-like peptide 1 (GLP-1) based therapy and an alternative treatment to type 2 diabetes mellitus (T2DM). Apart from its hypogliycemic effect, the drug has been also associated with the prevention of cardiovascular diseases, regulation of blood lipid and anti-inflammatory action. Reports indicate, however, that liraglutide can increase the risk of thyroid cancer and cause pancreatitis. Besides, studies demonstrated that some analogues of GLP-1 have a deleterious bone effect, while others demonstrated to be benefic to the bone. The aim of this study was to evaluate the effect in vitro of liraglutide in mouse pre-osteoblastic cells, MC3T3-E1. The results demonstrated that liraglutide significantly decreased the number of viable cells without inducing apoptosis. The mechanism of this effect is associated to the reactive oxygen species production (ROS), which resulted in an increase of cell autophagy. The decreased number of viable cells indicates therefore that liraglutide may affect the bone formation. |
